Primary Recipient

PROGENICS PHARMACEUTICALS, INC.

Amount

$580,717.00

Award Date

7/17/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

Award Title: HIV-1 Therapy with CCR5 mAb PRO 140 Award Description: PRO 140 is a humanized monoclonal antibody that binds to CCR5, a co-receptor that is the principal molecular portal used by HIV to enter and infect immune system cells. Some strains of